MCID: PLM035
MIFTS: 45

Pulmonary Eosinophilia

Categories: Respiratory diseases, Blood diseases

Aliases & Classifications for Pulmonary Eosinophilia

MalaCards integrated aliases for Pulmonary Eosinophilia:

Name: Pulmonary Eosinophilia 12 52 14 69
Asthmatic Pulmonary Eosinophilia 69

Classifications:



External Ids:

Disease Ontology 12 DOID:9498
ICD9CM 35 518.3
MeSH 42 D011657
ICD10 33 J82
UMLS 69 C0034068

Summaries for Pulmonary Eosinophilia

MalaCards based summary : Pulmonary Eosinophilia, also known as asthmatic pulmonary eosinophilia, is related to asthma and chronic eosinophilic pneumonia, and has symptoms including hemoptysis An important gene associated with Pulmonary Eosinophilia is IL5 (Interleukin 5), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Nitric Oxide and Methylprednisolone have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and bone, and related phenotypes are hematopoietic system and immune system

Related Diseases for Pulmonary Eosinophilia

Diseases related to Pulmonary Eosinophilia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 161)
id Related Disease Score Top Affiliating Genes
1 asthma 26.4 CCL11 CCL17 CCL5 CSF2 EPX IL13
2 chronic eosinophilic pneumonia 11.4
3 eosinophilic pneumonia 11.2
4 loeffler syndrome 11.2
5 papillary follicular thyroid adenocarcinoma 10.7 IL5 RNASE3
6 penis agenesis 10.7 CCL11 IL5
7 solitary cyst of breast 10.6 CCL11 IL5
8 crustacean allergy 10.6 IL5 RNASE3
9 subacute bacterial endocarditis 10.6 IL5 RNASE3
10 vulvar disease 10.6 CCL5 RNASE3
11 hidradenitis suppurativa 10.6 CCL11 CCL5
12 cytoplasmic body myopathy 10.6 IL13 IL5
13 orbit alveolar rhabdomyosarcoma 10.6 IL4 IL5
14 angioid streaks of choroid 10.5 IL4 IL5
15 allescheriosis 10.5 IL4 IL5
16 aortic arch interruption 10.5 IL13 IL5
17 urethral intrinsic sphincter deficiency 10.5 IL4 IL5
18 psychotic disorder 10.5 CCL11 IL4
19 signet ring cell adenocarcinoma 10.5 IL5 RNASE3
20 skin disease 10.5 IL5 RNASE3
21 histoplasmosis retinitis 10.5 IL4 IL5
22 retinal vascular disease 10.5 CCL11 IL4
23 myofibroma 10.5 IL13 IL5
24 chronic cholangitis 10.5 CCL11 IL4
25 indian tick typhus 10.5 CCL5 IL13
26 nonspecific interstitial pneumonia 10.5 CCL17 IL5
27 primary syringomyelia 10.4 EPX RNASE3
28 hypothyroidism due to deficient transcription factors involved in pituitary development or function 10.4 IL4 IL5
29 whistling face syndrome, recessive form 10.4 IL5 RNASE3
30 oropharyngeal cancer, childhood 10.4 CCL5 IL4
31 esophagus small cell carcinoma 10.4 IL13 IL5
32 goat milk allergy 10.4 IL13 IL4
33 philophthalmiasis 10.4 IL4 IL5
34 cecum adenoma 10.4 EPX RNASE3
35 sideroblastic anemia 10.4 CSF2 IL5
36 cow milk allergy 10.4 IL13 IL4
37 nasal cavity carcinoma in situ 10.3 CCL11 IL5 RNASE3
38 marasmus 10.3 IL4 IL5 RNASE3
39 x-linked intellectual disability, van esch type 10.3 IL4 IL5 RNASE3
40 orbital plasma cell granuloma 10.3 IL4 IL5 RNASE3
41 dermatitis herpetiformis 10.3 CCL5 IL5
42 vascular dementia 10.3 CCL5 IL4
43 nut allergy 10.3 IL4 IL5 RNASE3
44 clostridium difficile colitis 10.3 EPX RNASE3
45 anterior dislocation of lens 10.3 CCL11 IL4 RNASE3
46 frontal sinus schneiderian papilloma 10.3 IL13 IL5
47 gonococcal endophthalmia 10.3 CCL5 IL5
48 fanconi syndrome 10.3 CCL5 CSF2
49 cholesteatoma of middle ear 10.2 CCL11 IL13 IL5
50 antley-bixler syndrome with genital anomalies and disordered steroidogenesis 10.2 CCL11 IL13 IL5

Comorbidity relations with Pulmonary Eosinophilia via Phenotypic Disease Network (PDN): (show all 16)


Active Peptic Ulcer Disease Acute Cystitis
Bronchitis Chronic Kidney Failure
Chronic Myocardial Ischemia Decubitus Ulcer
Deficiency Anemia Esophagitis
Familial Atrial Fibrillation Heart Disease
Iron Deficiency Anemia Ischemic Heart Disease
Postinflammatory Pulmonary Fibrosis Protein-Energy Malnutrition
Respiratory Failure Schizophreniform Disorder

Graphical network of the top 20 diseases related to Pulmonary Eosinophilia:



Diseases related to Pulmonary Eosinophilia

Symptoms & Phenotypes for Pulmonary Eosinophilia

UMLS symptoms related to Pulmonary Eosinophilia:


hemoptysis

MGI Mouse Phenotypes related to Pulmonary Eosinophilia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.76 CCL11 CCL17 CCL5 CSF2 EPX IL13
2 immune system MP:0005387 9.56 IL5 CCL11 CCL17 CCL5 CSF2 EPX
3 respiratory system MP:0005388 9.02 CCL11 CSF2 IL13 IL4 IL5

Drugs & Therapeutics for Pulmonary Eosinophilia

Drugs for Pulmonary Eosinophilia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 61)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nitric Oxide Approved Phase 4 10102-43-9 145068
2
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
3
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
4
Omalizumab Approved, Investigational Phase 4 242138-07-4
5
Ciclesonide Approved, Investigational Phase 4 126544-47-6, 141845-82-1 444033
6
Budesonide Approved Phase 4 51333-22-3 63006 5281004
7 Adrenergic Agents Phase 4,Phase 2
8 Adrenergic Agonists Phase 4,Phase 2
9 Adrenergic beta-2 Receptor Agonists Phase 4,Phase 2
10 Adrenergic beta-Agonists Phase 4,Phase 2
11 Anti-Allergic Agents Phase 4,Phase 2
12 Anti-Asthmatic Agents Phase 4,Phase 2
13 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
14 Antioxidants Phase 4
15 Autonomic Agents Phase 4,Phase 2
16 Bromides Phase 4
17 Bronchodilator Agents Phase 4,Phase 2
18 Cholinergic Agents Phase 4
19 Cholinergic Antagonists Phase 4
20 Dermatologic Agents Phase 4,Phase 2
21 Endothelium-Dependent Relaxing Factors Phase 4
22
Fluticasone Phase 4,Phase 2 90566-53-3, 80474-14-2 62924 22833648
23 Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Phase 4,Phase 2
24 glucocorticoids Phase 4,Phase 3,Phase 2
25 Hormone Antagonists Phase 4,Phase 3,Phase 2
26 Hormones Phase 4,Phase 3,Phase 2
27 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
28 Muscarinic Antagonists Phase 4
29 Neurotransmitter Agents Phase 4,Phase 2
30 Parasympatholytics Phase 4
31 Peripheral Nervous System Agents Phase 4,Phase 2
32 Protective Agents Phase 4
33 Respiratory System Agents Phase 4,Phase 2
34
Salmeterol xinafoate Phase 4,Phase 2 94749-08-3 56801
35 Tiotropium Bromide Phase 4 136310-93-5
36 Vasodilator Agents Phase 4
37 Antiemetics Phase 4
38 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
39 Gastrointestinal Agents Phase 4
40 Methylprednisolone acetate Phase 4,Phase 3
41 Methylprednisolone Hemisuccinate Phase 4,Phase 3
42 Neuroprotective Agents Phase 4
43 Prednisolone acetate Phase 4,Phase 3
44 Prednisolone hemisuccinate Phase 4,Phase 3
45 Prednisolone phosphate Phase 4,Phase 3
46 Albuterol Phase 4,Phase 2
47 Antibodies Phase 4,Phase 3,Phase 2
48 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2
49 Immunoglobulins Phase 4,Phase 3,Phase 2
50 Tocolytic Agents Phase 4,Phase 2

Interventional clinical trials:

(show all 32)

id Name Status NCT ID Phase Drugs
1 Exhaled NO Based Treatment of Chronic Obstructive Pulmonary Disease (COPD), ICS/LABA Versus LAMA Unknown status NCT02546349 Phase 4 fluticasone/salmeterol, tiotropium
2 The Efficacy of Three Months-prednisolone Therapy for Chronic Eosinophilic Pneumonia Completed NCT00632554 Phase 4 prednisolone 0.5 mg/kg/day for three months;prednisolone 0.5 mg/kg/day for six months
3 Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients Completed NCT02654145 Phase 4 Mepolizumab 100mg SC;Albuterol/salbutamol MDIs;Omalizumab
4 Small Particle Steroids in Refractory Asthma Completed NCT01171365 Phase 4 Ciclesonide;Placebo
5 An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation Recruiting NCT02937168 Phase 4 Reslizumab;Fludeoxyglucose F 18 (FDG);Placebo
6 The RECONSTRUCT Study - Reconstructing Disease Mechanisms in Asthma Recruiting NCT03034005 Phase 4 Budesonide
7 A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma Completed NCT01285323 Phase 3 Reslizumab;Placebo
8 A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01270464 Phase 3 Reslizumab;Placebo
9 A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma Completed NCT01287039 Phase 3 Reslizumab;Placebo
10 Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control Completed NCT02281318 Phase 3 Placebo;SOC
11 Study of Mepolizumab Safety Syringe in Asthmatics Completed NCT03021304 Phase 3 Mepolizumab
12 Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma Completed NCT01508936 Phase 3 Reslizumab;Placebo
13 Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients Recruiting NCT02555371 Phase 3 Placebo
14 A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma Recruiting NCT03052725 Phase 3 reslizumab
15 Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) Recruiting NCT02836496 Phase 3 Mepolizumab 300 mg;Placebo matching mepolizumab;Active OCS capsules (5 mg prednisolone or prednisone);Placebo matching OCS capsules
16 Study of Mepolizumab Autoinjector in Asthmatics Active, not recruiting NCT03099096 Phase 3 Mepolizumab
17 A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects Active, not recruiting NCT02135692 Phase 3 SOC
18 Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma Enrolling by invitation NCT02559791 Phase 2, Phase 3 Placebo
19 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma Terminated NCT01290887 Phase 3 Reslizumab
20 Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study Terminated NCT02594332 Phase 3 Mepolizumab;Placebo
21 A Phase IIa Study of KHK4563 Completed NCT01412736 Phase 2 KHK4563;KHK4563;KHK4563;Placebo
22 Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma Completed NCT01312961 Phase 2 Dupilumab;Placebo (for Dupilumab);Fluticasone/Salmeterol combination therapy;Fluticasone monotherapy;Albuterol;Levalbuterol
23 A Study to Evaluate the Effectiveness of MEDI-563 in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Completed NCT01227278 Phase 2
24 Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma Recruiting NCT02560610 Phase 2 OC000459;Placebo
25 Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children Active, not recruiting NCT02377427 Phase 2 Mepolizumab
26 Usefulness of Exhaled NO in the Differential Diagnosis Acute Eosinophilic Pneumonia and Bacterial Pneumonia Unknown status NCT01152424
27 Daptomycin > 6 mg/kg/Day as Salvage Therapy in Patients With Complex Bone and Joint Infection: Cohort Study in a Regionalreference Center Completed NCT03209934
28 Lung MRI and Allergic Broncho-pulmonary Aspergillosis in Cystic Fibrosis Completed NCT02853175
29 European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank Recruiting NCT02852928
30 Functional Activity of Airway Eosinophils in Allergic Disease Recruiting NCT01026532
31 Exploring Asthma Exacerbations in Mepolizumab Treated Patients Not yet recruiting NCT03324230
32 Prevalence of Chronic Obstructive Pulmonary Disease (COPD) and Eosinophilia Among Primary Care Patients Not yet recruiting NCT03018808

Search NIH Clinical Center for Pulmonary Eosinophilia

Genetic Tests for Pulmonary Eosinophilia

Anatomical Context for Pulmonary Eosinophilia

MalaCards organs/tissues related to Pulmonary Eosinophilia:

39
Lung, T Cells, Bone, Testes, Bone Marrow, Heart, B Cells

Publications for Pulmonary Eosinophilia

Articles related to Pulmonary Eosinophilia:

(show top 50) (show all 292)
id Title Authors Year
1
Tropical pulmonary eosinophilia masquerading as asthma in a 5-year-old girl. ( 28488945 )
2017
2
Tropical pulmonary eosinophilia: effect of addition of corticosteroids after failure of diethylcarbamazine therapy. ( 28198995 )
2017
3
In vivo neutralization of I+4 and I^7 integrins inhibits eosinophil trafficking and prevents lung injury during tropical pulmonary eosinophilia in mice. ( 28736941 )
2017
4
Pulmonary Eosinophilia From Inhaled Colistin. ( 28065254 )
2017
5
Invasive pulmonary mucormycosis: rare presentation with pulmonary eosinophilia. ( 28454572 )
2017
6
Acetaminophen Use: An Unusual Cause of Drug-Induced Pulmonary Eosinophilia. ( 27445539 )
2016
7
Concurrent sensitization to Aspergillus Fumigatus in tropical pulmonary eosinophilia. ( 27374215 )
2016
8
Pulmonary eosinophilia associated to treatment with natalizumab. ( 27512514 )
2016
9
A rare presentation of hydropneumothorax in tropical pulmonary eosinophilia: cavitation and pneumonic consolidation in a child. ( 26376823 )
2015
10
Host lung immunity is severely compromised during tropical pulmonary eosinophilia: role of lung eosinophils and macrophages. ( 26489428 )
2015
11
Simple pulmonary eosinophilia associated with clozapine treatment. ( 25514065 )
2015
12
An Unusual Case of Foreign Body Aspiration Masquerading as Pulmonary Eosinophilia. ( 26266154 )
2015
13
Natural helper cells contribute to pulmonary eosinophilia by producing IL-13 via IL-33/ST2 pathway in a murine model of respiratory syncytial virus infection. ( 26044350 )
2015
14
Simple pulmonary eosinophilia found on follow-up computed tomography of oncologic patients. ( 25082475 )
2014
15
Tropical pulmonary eosinophilia--a review. ( 24135173 )
2013
16
Pulmonary eosinophilia caused by testosterone cypionate. ( 23998379 )
2013
17
Regulatory T cells prevent Th2 immune responses and pulmonary eosinophilia during respiratory syncytial virus infection in mice. ( 23926350 )
2013
18
A rare case of ethambutol induced pulmonary eosinophilia. ( 24250213 )
2013
19
Contribution of IL-33-activated type II innate lymphoid cells to pulmonary eosinophilia in intestinal nematode-infected mice. ( 22331917 )
2012
20
FICZ, a tryptophan photoproduct, suppresses pulmonary eosinophilia and Th2-type cytokine production in a mouse model of ovalbumin-induced allergic asthma. ( 22561122 )
2012
21
Interleukin-17 drives pulmonary eosinophilia following repeated exposure to Aspergillus fumigatus conidia. ( 22252873 )
2012
22
Tropical pulmonary eosinophilia misdiagnosed as miliary tuberculosis: a case report and literature review. ( 22172479 )
2012
23
A mouse model of airway disease: oncostatin M-induced pulmonary eosinophilia, goblet cell hyperplasia, and airway hyperresponsiveness are STAT6 dependent, and interstitial pulmonary fibrosis is STAT6 independent. ( 21160052 )
2011
24
Role of oxidants in interstitial lung diseases: pneumoconioses, constrictive bronchiolitis, and chronic tropical pulmonary eosinophilia. ( 22131646 )
2011
25
Acquired alpha 1-antitrypsin deficiency in tropical pulmonary eosinophilia. ( 21808138 )
2011
26
Regulator of calcineurin 1 (Rcan1) is required for the development of pulmonary eosinophilia in allergic inflammation in mice. ( 21741935 )
2011
27
Serum C3d levels in tropical pulmonary eosinophilia. ( 20424307 )
2010
28
Chlorogenic acid suppresses pulmonary eosinophilia, IgE production, and Th2-type cytokine production in an ovalbumin-induced allergic asthma: activation of STAT-6 and JNK is inhibited by chlorogenic acid. ( 20637839 )
2010
29
Levels of circulating IL-33 and eosinophil cationic protein in patients with hypereosinophilia or pulmonary eosinophilia. ( 20719375 )
2010
30
Oral tolerance inhibits pulmonary eosinophilia in a cockroach allergen induced model of asthma: a randomized laboratory study. ( 21092270 )
2010
31
Enhancement of ovalbumin-induced pulmonary eosinophilia by intranasal administration of alpha1-proteinase inhibitor type 2 antisense oligonucleotides. ( 19111575 )
2009
32
Pulmonary eosinophilia is attenuated by early responding CD8(+) memory T cells in a murine model of RSV vaccine-enhanced disease. ( 19594395 )
2009
33
Pulmonary eosinophilia. ( 19618037 )
2009
34
Pulmonary eosinophilia correlates with allergen deposition to the lower respiratory tract in a mouse model of asthma. ( 18537985 )
2008
35
A carbohydrate fraction, AIP1 from Artemisia iwayomogi suppresses pulmonary eosinophilia and Th2-type cytokine production in an ovalbumin-induced allergic asthma. Down-regulation of TNF-alpha expression in the lung. ( 18068107 )
2008
36
The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia. ( 18242596 )
2008
37
Transient pulmonary eosinophilia incidentally found on low-dose computed tomography: findings in 40 individuals. ( 18303297 )
2008
38
Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein. ( 18519743 )
2008
39
Clinical alterations and mRNA levels of IL-4 and IL-5 in bronchoalveolar cells of horses with transient pulmonary eosinophilia. ( 17996260 )
2008
40
The number of respiratory syncytial virus (RSV)-specific memory CD8 T cells in the lung is critical for their ability to inhibit RSV vaccine-enhanced pulmonary eosinophilia. ( 19017987 )
2008
41
Tropical pulmonary eosinophilia in a patient undergoing open heart surgery. ( 18285744 )
2008
42
Pulmonary eosinophilia. ( 18197481 )
2008
43
Differential role of gamma interferon in inhibiting pulmonary eosinophilia and exacerbating systemic disease in fusion protein-immunized mice undergoing challenge infection with respiratory syncytial virus. ( 18094193 )
2008
44
Eosinophilic pustular folliculitis associated with pulmonary eosinophilia. ( 17714146 )
2007
45
C5 modulates airway hyperreactivity and pulmonary eosinophilia during enhanced respiratory syncytial virus disease by decreasing C3a receptor expression. ( 17079327 )
2007
46
Tropical pulmonary eosinophilia: a rare cause of cough in immigrants to Australia. ( 17908009 )
2007
47
Tropical pulmonary eosinophilia: pathogenesis, diagnosis and management. ( 17940489 )
2007
48
A critical role for Pin1 in allergic pulmonary eosinophilia in rats. ( 17720236 )
2007
49
Elevated levels of fragmented laminin-5 gamma2-chain in bronchoalveolar lavage fluid from dogs with pulmonary eosinophilia. ( 16624727 )
2006
50
Parasitic pulmonary eosinophilia. ( 16612768 )
2006

Variations for Pulmonary Eosinophilia

Expression for Pulmonary Eosinophilia

Search GEO for disease gene expression data for Pulmonary Eosinophilia.

Pathways for Pulmonary Eosinophilia

Pathways related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

(show all 32)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.83 CCL11 CCL5 CSF2 EPX IL13 IL4
2
Show member pathways
13.65 CCL11 CCL17 CCL5 CCL7 CSF2 IL13
3
Show member pathways
13.46 CCL11 CCL17 CCL5 CCL7 CSF2 IL13
4
Show member pathways
13.36 CCL11 CCL17 CCL5 CCL7 IL13 IL4
5
Show member pathways
13.19 CCL11 CCL5 CSF2 IL13 IL4 IL5
6
Show member pathways
13.18 CCL11 CCL17 CCL5 CCL7 CSF2 IL13
7
Show member pathways
13.03 CCL11 CCL17 CCL5 CCL7 CSF2 IL13
8
Show member pathways
12.71 CCL11 EPX IL13 IL4 IL5 RNASE3
9
Show member pathways
12.69 CCL11 CCL17 CCL5 CCL7
10
Show member pathways
12.45 CSF2 IL13 IL4 IL5
11
Show member pathways
12.24 CSF2 IL4 IL5
12
Show member pathways
12.17 CCL11 CCL5 CCL7
13
Show member pathways
12.11 CSF2 IL13 IL4 IL5
14
Show member pathways
12.03 CCL11 CCL17 CCL7 CSF2 IL13 IL4
15
Show member pathways
12.02 IL13 IL4 IL5
16
Show member pathways
11.93 CCL11 CCL17 CCL5 CCL7
17 11.87 CSF2 IL4 IL5
18 11.86 CCL11 IL13 IL4
19 11.77 CSF2 IL4 IL5
20 11.73 CSF2 IL13 IL4 IL5
21 11.68 IL13 IL4 IL5
22
Show member pathways
11.65 CSF2 IL4 IL5
23 11.56 CCL11 CCL17 IL4 IL5
24 11.4 CCL5 CSF2 IL13 IL4
25 11.33 CCL11 CCL17 IL13 IL4 IL5
26 11.24 IL13 IL4 IL5
27 11.23 CCL11 CCL5 CSF2 IL13 IL4 IL5
28 11.17 IL4 IL5
29 11.14 IL13 IL4 IL5
30 11.1 CSF2 IL13 IL4 IL5
31 10.83 IL13 IL4 IL5
32 10.46 CCL11 CCL17 CCL5 CCL7 CSF2 IL13

GO Terms for Pulmonary Eosinophilia

Cellular components related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 CCL11 CCL17 CCL5 CCL7 CSF2 EPX
2 extracellular space GO:0005615 9.32 CCL11 CCL17 CCL5 CCL7 CSF2 EPX

Biological processes related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

(show all 30)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of GTPase activity GO:0043547 9.97 CCL11 CCL17 CCL5 CCL7 CSF2 IL5
2 cell-cell signaling GO:0007267 9.88 CCL17 CCL5 CCL7 IL13
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.85 CCL11 CCL17 CCL5 CCL7
4 positive regulation of cell migration GO:0030335 9.81 CCL11 CCL5 CCL7
5 cellular response to tumor necrosis factor GO:0071356 9.81 CCL11 CCL17 CCL5 CCL7
6 cellular response to interleukin-1 GO:0071347 9.78 CCL11 CCL17 CCL5 CCL7
7 cellular calcium ion homeostasis GO:0006874 9.77 CCL11 CCL5 CCL7
8 chemokine-mediated signaling pathway GO:0070098 9.76 CCL11 CCL17 CCL5 CCL7
9 neutrophil chemotaxis GO:0030593 9.73 CCL11 CCL17 CCL5 CCL7
10 inflammatory response GO:0006954 9.73 CCL11 CCL17 CCL5 CCL7 IL13 IL5
11 positive regulation of B cell proliferation GO:0030890 9.7 IL13 IL4 IL5
12 cellular response to interferon-gamma GO:0071346 9.67 CCL11 CCL17 CCL5 CCL7
13 negative regulation of endothelial cell apoptotic process GO:2000352 9.65 IL13 IL4
14 lymphocyte chemotaxis GO:0048247 9.64 CCL11 CCL17
15 innate immune response in mucosa GO:0002227 9.63 IL4 RNASE3
16 positive regulation of JAK-STAT cascade GO:0046427 9.63 CCL5 IL5
17 myeloid dendritic cell differentiation GO:0043011 9.62 CSF2 IL4
18 microglial cell activation GO:0001774 9.62 IL13 IL4
19 dendritic cell differentiation GO:0097028 9.61 CSF2 IL4
20 positive regulation of podosome assembly GO:0071803 9.61 CSF2 IL5
21 positive regulation of mast cell degranulation GO:0043306 9.6 IL13 IL4
22 positive regulation of immunoglobulin production GO:0002639 9.58 IL13 IL4
23 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.58 CCL5 CSF2 IL4
24 positive regulation of natural killer cell chemotaxis GO:2000503 9.57 CCL5 CCL7
25 regulation of proton transport GO:0010155 9.56 IL13 IL4
26 chemotaxis GO:0006935 9.55 CCL11 CCL17 CCL5 CCL7 IL4
27 negative regulation of complement-dependent cytotoxicity GO:1903660 9.54 IL13 IL4
28 eosinophil chemotaxis GO:0048245 9.5 CCL11 CCL5 CCL7
29 monocyte chemotaxis GO:0002548 9.26 CCL11 CCL17 CCL5 CCL7
30 immune response GO:0006955 9.23 CCL11 CCL17 CCL5 CCL7 CSF2 IL13

Molecular functions related to Pulmonary Eosinophilia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.5 CSF2 IL4 IL5
2 cytokine receptor binding GO:0005126 9.37 IL13 IL4
3 CCR1 chemokine receptor binding GO:0031726 9.26 CCL5 CCL7
4 chemokine activity GO:0008009 9.26 CCL11 CCL17 CCL5 CCL7
5 cytokine activity GO:0005125 9.23 CCL11 CCL17 CCL5 CCL7 CSF2 IL13
6 CCR4 chemokine receptor binding GO:0031729 9.16 CCL17 CCL5

Sources for Pulmonary Eosinophilia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....